Award Details:
Award Type: Accelerator
Award #: A-014
Proposal Title: Targeted Nanomedicine for Treating Arteriovenous Fistula Failure
PI(s): Yun Fang and Matthew Tirrell (UChicago)
Award Amount: $100,000.00
Application Cycle: Round 4 (Spring 2020)
Award Start Date: October 1, 2020
Award End Date: September 30, 2021
Abstract:
The prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) requiring hemodialysis continues to grow. In the US alone, there are over 450,000 individuals requiring hemodialysis, most of whom have an arteriovenous fistula (AVF) surgically created by a direct connection between a peripheral artery and vein to facilitate dialysis. The failure rate of newly created AVFs varies from 25-60%, largely due to narrowing of blood vessels (stenosis) near and after the AVF. The cost rises with access complications, mainly owing to new AVF creation, interventional procedures with angioplasty and stent placement, as well as prolonged catheter use. The annual cost of placement and maintenance of vascular access averages $2.8 billion in the U.S., accounting for 12% of all end-stage renal disease (ESRD) Medicare payments. Supported by our strong in vivo data and a patent-pending nanotechnology platform, we propose to develop an innovative targeted nanomedicine-based therapeutic strategy to reduce AVF failure.